Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Stock Rating Upgraded by Royal Bank of Canada

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) was upgraded by research analysts at Royal Bank of Canada to a “hold” rating in a note issued to investors on Monday, Zacks.com reports.

Recordati Industria Chimica e Farmaceutica Stock Performance

Recordati Industria Chimica e Farmaceutica stock opened at $52.25 on Monday. Recordati Industria Chimica e Farmaceutica has a 12-month low of $52.25 and a 12-month high of $52.25. The business’s 50-day moving average price is $52.22 and its two-hundred day moving average price is $51.82. The company has a quick ratio of 0.95, a current ratio of 1.36 and a debt-to-equity ratio of 0.73. The stock has a market cap of $10.78 billion, a PE ratio of 18.80 and a beta of 0.33.

Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) last posted its quarterly earnings results on Tuesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter. The business had revenue of $622.00 million during the quarter. Recordati Industria Chimica e Farmaceutica had a net margin of 17.41% and a return on equity of 30.78%.

Recordati Industria Chimica e Farmaceutica Company Profile

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.